RESCULA
LOE Approachingunoprostone isopropyl
NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 21h ago · AI intelligence enriched 4d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RESCULA (unoprostone isopropyl) is a prostaglandin F analog ophthalmic solution approved in 2000 for reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is administered as eye drops and works by increasing uveoscleral outflow of aqueous humor. The drug represents an established class of glaucoma therapy with well-characterized efficacy and safety.
LOE Approaching
Product faces moderate competitive pressure (30/100) with approaching loss of exclusivity, suggesting shrinking commercial teams and transition from growth to maintenance mode.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on RESCULA offers experience in mature product management and competitive market dynamics within ophthalmology, but limited growth trajectory. This role is best suited for professionals seeking experience in brand defense, generic competition strategy, and lifecycle management rather than product expansion.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.